nivolumab

Known as: NIVO 
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death… (More)
National Institutes of Health

Related topics

Related topics

5 relations
10 ML nivolumab 10 MG/ML Injection [Opdivo]Monoclonal Antibodiesantigen binding

Broader (1)

Antineoplastic Agents

Narrower (1)

MDX-1106

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
BACKGROUND Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
BACKGROUND Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small… (More)
  • figure 6
  • table 1
  • table 2
Is this relevant?
Review
2017
Review
2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
BACKGROUND Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Nivolumab in previously untreated melanoma without BRAF mutation.
BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
BACKGROUND Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
BACKGROUND Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
BACKGROUND Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Nivolumab plus ipilimumab in advanced melanoma.
BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?